Introduction
Modern medicine and the femtech sector are undergoing a dangerous transformation. They are shifting away from treating specific pathologies toward the pharmacological and digital optimization of the human being.
The reader will discover how measurable biomarkers are becoming ends in themselves, leading to the phenomenon of treating numbers rather than patients. This text analyzes the mechanism of apparent emancipation, where access to data replaces genuine clinical care.
Hormones as Optimization Tools and Cultural Symbols
The author points out that the line between therapy and enhancement blurs when hormones become symbols of success and youth. Treatment ends where the goal is no longer to restore function, but to achieve a state beyond the average.
A prime example is the Low-T market, which transforms non-specific symptoms of aging into a measurable deficiency. This leads to the medicalization of natural life processes and a retreat into numbers as a way to avoid the existential dread of aging.
Hormonal Diagnostics Require Integrating Results with Clinical Symptoms
Low testosterone levels in blood tests signify disease only when they coexist with specific clinical symptoms. A laboratory result alone is insufficient for a diagnosis of hypogonadism.
The author warns against treating the 'norm' as biological mediocrity. Without medical context, a patient may fall under the illusion that a higher hormone value automatically equates to better health—a fundamental error in the science of feedback loops.
The Difference Between Replacement Therapy and Biological Enhancement
Replacement therapy (replacement) aims to compensate for pathology, whereas enhancement maximizes a desired trait. Commercial approaches promote the latter, as the optimization market is far larger than the market for treating deficiencies.
The danger here lies in the conflict of interest within direct-to-consumer clinics. The patient pays an entity that simultaneously assesses their needs. This can lead to ignoring risks—such as the inhibition of spermatogenesis or increased blood pressure—in favor of the promise of reaching one's full potential.
Summary
Technology promising total control over the body may become a new form of dependency. The patient leaves the paternalistic doctor's office only to enter the ecosystem of a private platform, where the asymmetry of knowledge shifts into algorithmic code.
True autonomy does not consist of owning an app or striving for optimal numbers. It consists of the right to be a biological human being in a world that demands constant optimization.
Frequently Asked Questions
Where does the treatment of hormonal deficiencies end and pharmacological optimization of the body begin?
The boundary between treatment and optimization does not run within the drug molecule itself, but depends on the purpose for which a given substance is used. The same therapy can be a rational treatment for a disease in one patient, while for another, it is an element of an aspirational bodily project.
When does a low testosterone level in blood tests actually indicate a disease that requires treatment?
Low testosterone levels indicate a disease requiring treatment only when they co-occur with clinical symptoms characteristic of this deficiency. Diagnosis also requires confirmation of the result in two separate fasting morning measurements.
What is the difference between medical testosterone replacement therapy and attempts at body optimization, and what are the risks associated with a commercial approach to these procedures?
Replacement therapy aims to restore physiological function disrupted by deficiency, whereas optimization (enhancement) attempts to exceed the point of sufficient functionality to achieve above-average effects. The risk in a commercial approach is a conflict of interest, where the business model may prioritize the sale of therapy over reliable clinical qualification, leading to the omission of risks such as loss of fertility or polycythemia.
What are the real risks and benefits of hormone therapies for men and women compared to the narratives appearing in public discourse?
In men, exogenous testosterone can inhibit spermatogenesis and reduce testicular volume; however, for most, fertility returns after discontinuing the drug. In women, HRT is the most effective treatment for menopause symptoms and prevents bone mass loss, but its safety depends on the patient's individual profile, dose, and route of administration (e.g., transdermal therapy is associated with a lower risk of thrombosis than oral therapy). In both cases, public discourse often replaces complex medical knowledge with emotional narratives based on fear or unrealistic hope.
What are the main risks and errors in the interpretation of hormone therapy during menopause?
The main risks include undertreatment resulting from fear and excessive pharmacologization, including the use of hormones without clinical grounds or insufficient progestogen protection in the presence of a uterus. Interpretation errors result from selective choice of arguments, incorrect risk framing (relative vs absolute risk), as well as the influence of social media and the nocebo effect.
When does the use of testosterone in women stop being a medical treatment and become an attempt at body optimization?
The use of testosterone ceases to be a medical treatment when the goal of the intervention is not to restore function lost due to pathology, but to achieve traits that are better than sufficient. This happens during the transition from treating specific disorders (e.g., HSDD in postmenopausal women) to an attempt at general body optimization and improving a healthy person.
Why do we currently strive for hormonal optimization instead of accepting the aging process?
The pursuit of hormonal optimization allows us to transform the existentially difficult problem of aging into a measurable and concrete biological deficit. This is psychologically attractive because it replaces the analysis of complex causes (e.g., relationships or stress) with a simple laboratory solution.
Why can striving for optimal hormone levels based solely on test results be harmful, and what does the process of ending such therapy look like?
Striving for optimal hormone levels based solely on test results can lead to 'treating the number' rather than the clinical situation, which realistically alters the body's physiology and can become a biological event. The process of ending therapy involves so-called exit costs, requiring a plan, supervision, and acceptance of an adaptation period due to the time needed for the hormonal axis to regain activity.
Does greater patient access to medical data and technology mean an increase in their actual autonomy in the treatment process?
Greater access to data and technology does not automatically mean an increase in real autonomy, as it may lead only to so-called consumer sovereignty driven by the market and algorithms. True agency requires maintaining a relationship with a physician, who acts as an epistemic filter, verifying medical indications and protecting the patient from erroneous decisions.
How do femtech tools affect women's real autonomy in managing their own health?
Femtech tools can increase women's autonomy by decentralizing knowledge about their own bodies and supporting informed health decisions. At the same time, they may create new dependencies on algorithms and business models, and the mere provision of data does not always translate into real agency if this information is unreliable or difficult to translate into safe action.
Are fertility monitoring apps and devices truly as precise and safe as their marketing claims?
Some fertility monitoring devices and apps can be misleading through a so-called 'aesthetic of precision,' where marketing claims of effectiveness are based on studies with methodological errors. The actual effectiveness of these methods often depends on user behavior and is lower than in the case of perfect use, and many available studies on them are characterized by low or moderate quality.
Do femtech applications actually increase patient autonomy in health management?
Femtech apps do not eliminate knowledge asymmetry; instead, they shift it from the doctor's office to the code of algorithms and platforms, which are less understandable to the user. Autonomy is further limited by potential conflicts of interest among app creators, as well as poor quality of privacy protection and medical criteria.
How can cycle-tracking apps threaten women's privacy despite formal consents for data processing?
Apps can threaten privacy through so-called inferential privacy, which involves drawing sensitive conclusions (e.g., about pregnancy) based on seemingly harmless biological and behavioral data. Users are unable to predict all future analytical models, meaning that formal consent for data processing does not equate to full awareness of the extent of its use.
Do online communities and femtech apps actually help women regain agency in diagnosing their health?
Online communities and apps help women counteract isolation by providing a language to describe experiences and validating their subjectivity. However, they can lead to erroneous causal conclusions and an unrepresentative picture of risk due to the dominance of intense, negative narratives over statistical data.
Is self-management of health and medical procedures a genuine emancipation of the patient, or merely a transfer of risk responsibility from institutions to the individual?
The decentralization of health management increases patient agency if tools are well-validated and the cost of error is low. However, it becomes a semblance of emancipation and a privatization of risk in situations where data is poorly verified, consequences of errors are serious, and responsibility for them falls on the user rather than the institution.
Why can fertility coaching services be dangerous despite an appearance of professionalism?
Fertility coaching services can be dangerous when coaches cross the line from education to quasi-diagnostics, interpreting tests or suggesting supplementation without bearing medical responsibility. They often utilize so-called 'borrowed authority' (e.g., through attire or terminology), offering simple and satisfying answers instead of reliable, evidence-based medical knowledge.
Do femtech tools and access to data actually give women more control over their health, or do they instead impose a new kind of pressure and responsibility?
Femtech tools can increase women's agency by providing data and revealing patterns; however, without control over that information, this control remains incomplete. At the same time, this technology may exert new pressure, turning women into managers of their own risk and introducing a moral obligation to optimize their biology, where ignorance is sometimes interpreted as neglect.
Does using femtech tools actually increase women's agency in taking care of their health?
Femtech increases women's agency when it provides validated information, clearly communicates uncertainty, does not misappropriate data, and does not force constant subscriptions. Real agency does not stem from simply owning an app, but from the ability to understand data, question algorithms, and make decisions without economic or social coercion.
